Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2008

01-05-2008 | Review Paper

Gastrointestinal Manifestations of Systemic Sclerosis

Authors: Robyn Domsic, Kenneth Fasanella, Klaus Bielefeldt

Published in: Digestive Diseases and Sciences | Issue 5/2008

Login to get access

Abstract

Systemic sclerosis is a chronic disorder of connective tissue that affects the gastrointestinal tract in more than 80% of patients. Changes in neuromuscular function with progressive fibrosis of smooth muscle within the muscularis propria impair normal motor function, which may secondarily alter transit and nutrient absorption. Esophageal manifestations with gastroesophageal reflux and dysphagia are the most common visceral manifestation of the disease, often requiring more intense acid-suppressive medication. Gastric involvement may lead to gastroparesis, which can be found in up to 50% of patients. Severe small bowel disease can present as chronic intestinal pseudo-obstruction with distended loops of small intestine, bacterial overgrowth, impaired absorption and progressive development of nutritional deficiencies. While not studied as extensively, systemic sclerosis often also affects colorectal function resulting in constipation, diarrhea or fecal incontinence. Nutritional support and prokinetics have been used with some success to manage gastric and small or large bowel involvement in patients with systemic sclerosis. Despite advances in management, significant gastrointestinal manifestations of systemic sclerosis still carry a poor prognosis with a five-year mortality exceeding 50%.
Literature
1.
go back to reference Krishnan E, Furst DE (2005) Systemic sclerosis mortality in the United States: 1979–1998. Eur J Epidemiol 20:855–861PubMedCrossRef Krishnan E, Furst DE (2005) Systemic sclerosis mortality in the United States: 1979–1998. Eur J Epidemiol 20:855–861PubMedCrossRef
2.
go back to reference Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, LeRoy EC, McGregor AR, Diat F, Rosal EJ (1989) Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 32:998–1006PubMedCrossRef Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, LeRoy EC, McGregor AR, Diat F, Rosal EJ (1989) Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 32:998–1006PubMedCrossRef
3.
go back to reference Szamosi S, Szekanecz Z, Szucs G (2006) Gastrointestinal manifestations in Hungarian scleroderma patients. Rheumatol Int 26:1120–1124PubMedCrossRef Szamosi S, Szekanecz Z, Szucs G (2006) Gastrointestinal manifestations in Hungarian scleroderma patients. Rheumatol Int 26:1120–1124PubMedCrossRef
5.
go back to reference Steen VD, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef Steen VD, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437–2444PubMedCrossRef
6.
go back to reference LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed
7.
go back to reference Sjogren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282PubMedCrossRef Sjogren RW (1994) Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37:1265–1282PubMedCrossRef
8.
go back to reference Greydanus MP, Camilleri M (1989) Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 96:110–115PubMed Greydanus MP, Camilleri M (1989) Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 96:110–115PubMed
9.
go back to reference Rees WD, Leigh RJ, Christofides ND, Bloom SR, Turnberg LA (1982) Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology 83:575–580PubMed Rees WD, Leigh RJ, Christofides ND, Bloom SR, Turnberg LA (1982) Interdigestive motor activity in patients with systemic sclerosis. Gastroenterology 83:575–580PubMed
10.
go back to reference DeSchryver-Kecskemeti K, Clouse RE (1989) Perineural and intraneural inflammatory infiltrates in the intestines of patients with systemic connective-tissue disease. Arch Pathol Lab Med 113:394–398PubMed DeSchryver-Kecskemeti K, Clouse RE (1989) Perineural and intraneural inflammatory infiltrates in the intestines of patients with systemic connective-tissue disease. Arch Pathol Lab Med 113:394–398PubMed
11.
go back to reference Malandrini A, Selvi E, Villanova M, Berti G, Sabadini L, Salvadori C, Gambelli S, De Stefano R, Vernillo R, Marcolongo R, Guazzi G (2000) Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol 27:1203–1206PubMed Malandrini A, Selvi E, Villanova M, Berti G, Sabadini L, Salvadori C, Gambelli S, De Stefano R, Vernillo R, Marcolongo R, Guazzi G (2000) Autonomic nervous system and smooth muscle cell involvement in systemic sclerosis: ultrastructural study of 3 cases. J Rheumatol 27:1203–1206PubMed
12.
go back to reference Roberts CGP, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM (2006) A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55:1697–1703PubMedCrossRef Roberts CGP, Hummers LK, Ravich WJ, Wigley FM, Hutchins GM (2006) A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55:1697–1703PubMedCrossRef
13.
14.
go back to reference Howe S, Eaker EY, Sallustio JE, Peebles C, Tan EM, Williams RC (1994) Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 94:761–770PubMedCrossRef Howe S, Eaker EY, Sallustio JE, Peebles C, Tan EM, Williams RC (1994) Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 94:761–770PubMedCrossRef
15.
go back to reference Goldblatt F, Gordon TP and Waterman SA (2002) Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 123:1144–1150PubMedCrossRef Goldblatt F, Gordon TP and Waterman SA (2002) Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 123:1144–1150PubMedCrossRef
16.
go back to reference Eaker EY, Kuldau JG, Verne GN, Ross SO, Sallustio JE (1999) Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 133:551–556PubMedCrossRef Eaker EY, Kuldau JG, Verne GN, Ross SO, Sallustio JE (1999) Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 133:551–556PubMedCrossRef
17.
go back to reference Denton CP, Black CM (2000) Scleroderma and related disorders: therapeutic aspects. Best Pract Res Clin Rheumatol 14:17–35CrossRef Denton CP, Black CM (2000) Scleroderma and related disorders: therapeutic aspects. Best Pract Res Clin Rheumatol 14:17–35CrossRef
18.
go back to reference Denton CP, Black CM, Abraham DJ (2006) Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2:134–144PubMedCrossRef Denton CP, Black CM, Abraham DJ (2006) Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2:134–144PubMedCrossRef
19.
go back to reference Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic M (2006) Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107:463–466PubMedCrossRef Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic M (2006) Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 107:463–466PubMedCrossRef
20.
go back to reference Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, Hachulla E, Philippe P, Sibilia J, Rabian C, Chevret S, Gluckman E (2002) Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 119:726–739PubMedCrossRef Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, Hachulla E, Philippe P, Sibilia J, Rabian C, Chevret S, Gluckman E (2002) Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 119:726–739PubMedCrossRef
21.
go back to reference McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE (2002) High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100:1602–1610PubMed McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE (2002) High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100:1602–1610PubMed
22.
go back to reference Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C-S, Godwin JD, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes MD, McDonagh KT, McLaughlin B, Molitor JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener MH, Seibold JR, Sullivan KM, Furst DE (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110:1388–1396PubMedCrossRef Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C-S, Godwin JD, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes MD, McDonagh KT, McLaughlin B, Molitor JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener MH, Seibold JR, Sullivan KM, Furst DE (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110:1388–1396PubMedCrossRef
23.
go back to reference Soto-Rojas AE, Kraus A (2002) The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res 33:95–106PubMedCrossRef Soto-Rojas AE, Kraus A (2002) The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res 33:95–106PubMedCrossRef
24.
go back to reference Ostojic P, Damjanov N (2006) Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol 25:453–457PubMedCrossRef Ostojic P, Damjanov N (2006) Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol 25:453–457PubMedCrossRef
25.
go back to reference Hamel-Roy J, Devroede G, Arhan P, Tetreault L, Duranceau A, Menard HA (1985) Comparative esophageal and anorectal motility in scleroderma. Gastroenterology 88:1–7PubMed Hamel-Roy J, Devroede G, Arhan P, Tetreault L, Duranceau A, Menard HA (1985) Comparative esophageal and anorectal motility in scleroderma. Gastroenterology 88:1–7PubMed
26.
go back to reference Airo P, Della Casa D, Danieli E, Missale G, Cattaneo R, Cestari R (2005) Oesophageal manometry in early and definite systemic sclerosis. Clin Rheumatol 24:370–376PubMedCrossRef Airo P, Della Casa D, Danieli E, Missale G, Cattaneo R, Cestari R (2005) Oesophageal manometry in early and definite systemic sclerosis. Clin Rheumatol 24:370–376PubMedCrossRef
27.
go back to reference Bassotti G, Battaglia E, Debernardi V, Germani U, Quiriconi F, Dughera L, Buonafede G, Puiatti P, Morelli A, Spinozzi F, Mioli PR, Emanuelli G (1998) Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum 40:2252–2259CrossRef Bassotti G, Battaglia E, Debernardi V, Germani U, Quiriconi F, Dughera L, Buonafede G, Puiatti P, Morelli A, Spinozzi F, Mioli PR, Emanuelli G (1998) Esophageal dysfunction in scleroderma: relationship with disease subsets. Arthritis Rheum 40:2252–2259CrossRef
28.
go back to reference Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J, Chaussade S, Kahan A (2005) Prevalence of Barrett’s esophagus in systemic sclerosis. Arthritis Rheum 52:2882–2888PubMedCrossRef Wipff J, Allanore Y, Soussi F, Terris B, Abitbol V, Raymond J, Chaussade S, Kahan A (2005) Prevalence of Barrett’s esophagus in systemic sclerosis. Arthritis Rheum 52:2882–2888PubMedCrossRef
29.
go back to reference Basilisco G, Carola F, Vanoli M, Bianchi P, Barbera R (1996) Oesophageal acid clearance in patients with systemic sclerosis: effect of body position. Eur J Gastroenterol Hepatol 8:205–209PubMedCrossRef Basilisco G, Carola F, Vanoli M, Bianchi P, Barbera R (1996) Oesophageal acid clearance in patients with systemic sclerosis: effect of body position. Eur J Gastroenterol Hepatol 8:205–209PubMedCrossRef
30.
go back to reference Lock G, Zeuner M, Straub RH, Hein R, Lang B, Scholmerich J, Holstege A (1997) Esophageal manometry in systemic sclerosis: screening procedure or confined to symptomatic patients? Rheumatol Int 17:61–66PubMedCrossRef Lock G, Zeuner M, Straub RH, Hein R, Lang B, Scholmerich J, Holstege A (1997) Esophageal manometry in systemic sclerosis: screening procedure or confined to symptomatic patients? Rheumatol Int 17:61–66PubMedCrossRef
31.
go back to reference Hendel L, Hage E, Hendel J, Stentoft P (1992) Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 6:565–577PubMedCrossRef Hendel L, Hage E, Hendel J, Stentoft P (1992) Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 6:565–577PubMedCrossRef
32.
go back to reference Johnson DA, Drane WE, Curran J, Benjamin SB, Chobanian SJ, Karvelis K, Cattau EL Jr (1987) Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch Intern Med 147:1597–1601PubMedCrossRef Johnson DA, Drane WE, Curran J, Benjamin SB, Chobanian SJ, Karvelis K, Cattau EL Jr (1987) Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities. Arch Intern Med 147:1597–1601PubMedCrossRef
33.
go back to reference Mercado U, Arroyo de Anda R, Avendano L, Araiza-Casillas R, Avendano-Reyes M (2005) Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities. Clin Exp Rheumatol 23:685–688PubMed Mercado U, Arroyo de Anda R, Avendano L, Araiza-Casillas R, Avendano-Reyes M (2005) Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities. Clin Exp Rheumatol 23:685–688PubMed
34.
go back to reference Richter JE, Sabesin SM, Kogut DG, Kerr RM, Wruble LD, Collen MJ (1996) Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 91:1766–1772PubMed Richter JE, Sabesin SM, Kogut DG, Kerr RM, Wruble LD, Collen MJ (1996) Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 91:1766–1772PubMed
35.
go back to reference Wang SJ, La JL, Chen DY, Chen YH, Hsieh TY, Lin WY (2002) Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 21:43–45PubMedCrossRef Wang SJ, La JL, Chen DY, Chen YH, Hsieh TY, Lin WY (2002) Effects of cisapride on oesophageal transit of solids in patients with progressive systemic sclerosis. Clin Rheumatol 21:43–45PubMedCrossRef
36.
go back to reference Mansour KA, Malone CE (1995) Surgery for scleroderma of the esophagus: A 12-year experience. Ann Thorac Surg 60:227PubMed Mansour KA, Malone CE (1995) Surgery for scleroderma of the esophagus: A 12-year experience. Ann Thorac Surg 60:227PubMed
37.
go back to reference Orringer MB, Dabich L, Zarafonetis CJ, Sloan H (1976) Gastroesophageal reflux in esophageal scleroderma: diagnosis and implications. Ann Thorac Surg 22:120–130PubMedCrossRef Orringer MB, Dabich L, Zarafonetis CJ, Sloan H (1976) Gastroesophageal reflux in esophageal scleroderma: diagnosis and implications. Ann Thorac Surg 22:120–130PubMedCrossRef
38.
go back to reference Poirier NC, Taillefer R, Topart P, Duranceau A (1994) Antireflux operations in patients with scleroderma. Ann Thorac Surg 58:66–72PubMedCrossRef Poirier NC, Taillefer R, Topart P, Duranceau A (1994) Antireflux operations in patients with scleroderma. Ann Thorac Surg 58:66–72PubMedCrossRef
39.
go back to reference Watson DI, Jamieson GG, Bessell JR, Devitt PG (2006) Laparoscopic fundoplication in patients with an aperistaltic esophagus and gastroesophageal reflux. Dis Esophagus 19:94–98PubMedCrossRef Watson DI, Jamieson GG, Bessell JR, Devitt PG (2006) Laparoscopic fundoplication in patients with an aperistaltic esophagus and gastroesophageal reflux. Dis Esophagus 19:94–98PubMedCrossRef
41.
go back to reference Segel MC, Campbell WL, Medsger TA, Roumm AD (1985) Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: is increased patient screening necessary? Gastroenterology 89:485–488PubMed Segel MC, Campbell WL, Medsger TA, Roumm AD (1985) Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: is increased patient screening necessary? Gastroenterology 89:485–488PubMed
42.
go back to reference Poelmans J, Tack J (2005) Extraoesophageal manifestations of gastro-oesophageal reflux. Gut 54:1492–1499 Poelmans J, Tack J (2005) Extraoesophageal manifestations of gastro-oesophageal reflux. Gut 54:1492–1499
43.
go back to reference Kinuya K, Nakajima K, Kinuya S, Michigishi T, Tonami N, Takehara K (2001) Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 15:97–101PubMedCrossRef Kinuya K, Nakajima K, Kinuya S, Michigishi T, Tonami N, Takehara K (2001) Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 15:97–101PubMedCrossRef
44.
go back to reference Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Scholmerich J, Holstege A (1998) Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 93:341–345PubMedCrossRef Lock G, Pfeifer M, Straub RH, Zeuner M, Lang B, Scholmerich J, Holstege A (1998) Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 93:341–345PubMedCrossRef
45.
go back to reference Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF, Courtois H (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45:346–354PubMedCrossRef Marie I, Dominique S, Levesque H, Ducrotte P, Denis P, Hellot MF, Courtois H (2001) Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 45:346–354PubMedCrossRef
46.
go back to reference Troshinsky MB, Kane GC, Varga J, Cater JR, Fish JE, Jimenez SA, Castell DO (1994) Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 121:6–10PubMed Troshinsky MB, Kane GC, Varga J, Cater JR, Fish JE, Jimenez SA, Castell DO (1994) Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 121:6–10PubMed
47.
go back to reference Franck-Larsson K, Hedenstrom H, Dahl R, Ronnblom A (2003) Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand J Rheumatol 32:348–355PubMedCrossRef Franck-Larsson K, Hedenstrom H, Dahl R, Ronnblom A (2003) Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand J Rheumatol 32:348–355PubMedCrossRef
48.
go back to reference Marie I, Levesque H, Ducrotte P, Denis P, Hellot M-F, Benichou J, Cailleux N, Courtois H (2001) Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 96:77–83PubMedCrossRef Marie I, Levesque H, Ducrotte P, Denis P, Hellot M-F, Benichou J, Cailleux N, Courtois H (2001) Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 96:77–83PubMedCrossRef
49.
go back to reference Sridhar KR, Lange RC, Magyar L, Soykan I, McCallum RW (1998) Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J Lab Clin Med 132:541–546PubMedCrossRef Sridhar KR, Lange RC, Magyar L, Soykan I, McCallum RW (1998) Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J Lab Clin Med 132:541–546PubMedCrossRef
51.
go back to reference McNearney T, Lin X, Shrestha J, Lisse J, Chen JDZ (2002) Characterization of gastric myoelectrical rhythms in patients with systemic sclerosis using multichannel surface electrogastrography. Dig Dis Sci 47:690–698PubMedCrossRef McNearney T, Lin X, Shrestha J, Lisse J, Chen JDZ (2002) Characterization of gastric myoelectrical rhythms in patients with systemic sclerosis using multichannel surface electrogastrography. Dig Dis Sci 47:690–698PubMedCrossRef
52.
go back to reference Pfaffenbach B, Adamek RJ, Hagemann D, Busch S, Hoffmann K, Altmeyer P, Schaffstein J, Wegener M (1996) Effect of progressive systemic sclerosis on antral myoelectrical activity and gastric emptying. Z Gastroenterol 34:517–521PubMed Pfaffenbach B, Adamek RJ, Hagemann D, Busch S, Hoffmann K, Altmeyer P, Schaffstein J, Wegener M (1996) Effect of progressive systemic sclerosis on antral myoelectrical activity and gastric emptying. Z Gastroenterol 34:517–521PubMed
53.
go back to reference Marie I, Levesque H, Ducrotté P, Denis P, Benichou J, Hellot MF, Cailleux N, Le Loët X, Joly P, Lauret P, Courtois H (1998) Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum 41:1874–1883PubMedCrossRef Marie I, Levesque H, Ducrotté P, Denis P, Benichou J, Hellot MF, Cailleux N, Le Loët X, Joly P, Lauret P, Courtois H (1998) Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum 41:1874–1883PubMedCrossRef
54.
go back to reference Fiorucci S, Distrutti E, Bassotti G, Gerli R, Chiucchiu S, Betti C, Santucci L, Morelli A (1994) Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol 29:807–813PubMedCrossRef Fiorucci S, Distrutti E, Bassotti G, Gerli R, Chiucchiu S, Betti C, Santucci L, Morelli A (1994) Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol 29:807–813PubMedCrossRef
55.
go back to reference Fiorucci S, Distrutti E, Gerli R, Morelli A (1994) Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol 89:550–555PubMed Fiorucci S, Distrutti E, Gerli R, Morelli A (1994) Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol 89:550–555PubMed
56.
go back to reference Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJ (1987) Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 93:311–315PubMed Horowitz M, Maddern GJ, Maddox A, Wishart J, Chatterton BE, Shearman DJ (1987) Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 93:311–315PubMed
57.
go back to reference Linke R, Meier M, Muenzing W, Folwaczny C, Schnell O, Tatsch K (2005) Prokinetic therapy: what can be measured by gastric scintigraphy? Nucl Med Commun 26:527–233PubMedCrossRef Linke R, Meier M, Muenzing W, Folwaczny C, Schnell O, Tatsch K (2005) Prokinetic therapy: what can be measured by gastric scintigraphy? Nucl Med Commun 26:527–233PubMedCrossRef
58.
go back to reference Sebastian S, O’Morain CA, Buckley MJ (2003) Review article: current therapeutic options for gastric antral vascular ectasia. Aliment Pharmacol Ther 15:157–165CrossRef Sebastian S, O’Morain CA, Buckley MJ (2003) Review article: current therapeutic options for gastric antral vascular ectasia. Aliment Pharmacol Ther 15:157–165CrossRef
59.
go back to reference Pickhardt PJ (1999) The “hide-bound” bowel sign. Radiology 213:837–838PubMed Pickhardt PJ (1999) The “hide-bound” bowel sign. Radiology 213:837–838PubMed
60.
go back to reference Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R (1998) Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology 45:1643–1650PubMed Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R (1998) Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology 45:1643–1650PubMed
61.
go back to reference Kaye SA, Lim SG, Taylor M, Patel S, Gillespie S, Black CM (1995) Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Rheumatology 34:265–269CrossRef Kaye SA, Lim SG, Taylor M, Patel S, Gillespie S, Black CM (1995) Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome. Rheumatology 34:265–269CrossRef
62.
go back to reference Wegener M, Adamek RJ, Wedmann B, Jergas M, Altmeyer P (1994) Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci 39:2209–2215PubMedCrossRef Wegener M, Adamek RJ, Wedmann B, Jergas M, Altmeyer P (1994) Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci 39:2209–2215PubMedCrossRef
63.
go back to reference Stellaard F, Sauerbruch T, Luderschmidt CH, Leisner B, Paumgartner G (1987) Intestinal involvement in progressive systemic sclerosis detected by increased unconjugated serum bile acids. Gut 28:446–450PubMedCrossRef Stellaard F, Sauerbruch T, Luderschmidt CH, Leisner B, Paumgartner G (1987) Intestinal involvement in progressive systemic sclerosis detected by increased unconjugated serum bile acids. Gut 28:446–450PubMedCrossRef
64.
go back to reference Emmanuel AV, Shand AG, Kamm MA (2004) Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther 19:687–694PubMedCrossRef Emmanuel AV, Shand AG, Kamm MA (2004) Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther 19:687–694PubMedCrossRef
65.
go back to reference Soudah HC, Hasler WL, Owyang C (1991) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 325:1461–1467PubMedCrossRef Soudah HC, Hasler WL, Owyang C (1991) Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 325:1461–1467PubMedCrossRef
66.
go back to reference Verne GN, Eaker EY, Hardy E, Sninsky CA (1995) Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 40:1892–1901PubMedCrossRef Verne GN, Eaker EY, Hardy E, Sninsky CA (1995) Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 40:1892–1901PubMedCrossRef
67.
go back to reference Perlemuter G, Cacoub P, Chaussade S, Wechsler B, Couturier D, Piette JC (1999) Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum 42:1545–1549PubMedCrossRef Perlemuter G, Cacoub P, Chaussade S, Wechsler B, Couturier D, Piette JC (1999) Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum 42:1545–1549PubMedCrossRef
68.
go back to reference Attar A, Flourié B, Rambaud J, Franchisseur C, Ruszniewski P, Bouhnik Y (1999) Antibiotic efficacy in small intestinal bacterial overgrowth–related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117:794–797PubMedCrossRef Attar A, Flourié B, Rambaud J, Franchisseur C, Ruszniewski P, Bouhnik Y (1999) Antibiotic efficacy in small intestinal bacterial overgrowth–related chronic diarrhea: a crossover, randomized trial. Gastroenterology 117:794–797PubMedCrossRef
69.
go back to reference Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK (2005) Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115:178–181PubMed Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK (2005) Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115:178–181PubMed
70.
go back to reference Grabowski G, Grant JP (1989) Nutritional support in patients with systemic scleroderma. J Parenter Enteral Nutr 13:147–151CrossRef Grabowski G, Grant JP (1989) Nutritional support in patients with systemic scleroderma. J Parenter Enteral Nutr 13:147–151CrossRef
71.
go back to reference Quiroz ES, Flannery MT, Martinez EJ, Warner EA (1995) Pneumatosis cystoides intestinalis in progressive systemic sclerosis: a case report and literature review. Am J Med Sci 310:252–255PubMed Quiroz ES, Flannery MT, Martinez EJ, Warner EA (1995) Pneumatosis cystoides intestinalis in progressive systemic sclerosis: a case report and literature review. Am J Med Sci 310:252–255PubMed
72.
go back to reference Trezza M, Krogh K, Egekvist H, Bjerring P, Laurberg S (1999) Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol 34:409–413PubMedCrossRef Trezza M, Krogh K, Egekvist H, Bjerring P, Laurberg S (1999) Bowel problems in patients with systemic sclerosis. Scand J Gastroenterol 34:409–413PubMedCrossRef
73.
go back to reference Engel A, Kamm M, Talbot I (1994) Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence. Gut 35:857–859PubMedCrossRef Engel A, Kamm M, Talbot I (1994) Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence. Gut 35:857–859PubMedCrossRef
74.
go back to reference deSouza N, Williams A, Wilson H, Gilderdale D, Coutts G, Black C (1998) Fecal incontinence in scleroderma: assessment of the anal sphincter with thin-section endoanal MR imaging. Radiology 208:529–535PubMed deSouza N, Williams A, Wilson H, Gilderdale D, Coutts G, Black C (1998) Fecal incontinence in scleroderma: assessment of the anal sphincter with thin-section endoanal MR imaging. Radiology 208:529–535PubMed
75.
go back to reference Jaffin BW, Chang P, Spiera H (1997) Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications. J Clin Gastroenterol 25:513–517PubMedCrossRef Jaffin BW, Chang P, Spiera H (1997) Fecal incontinence in scleroderma. Clinical features, anorectal manometric findings, and their therapeutic implications. J Clin Gastroenterol 25:513–517PubMedCrossRef
76.
go back to reference Heyt GJ, Oh MK, Alemzadeh N, Rivera S, Jimenez SA, Rattan S, Cohen S, Dimarino AJ (2004) Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence. Dig Dis Sci 49:1040–1045PubMedCrossRef Heyt GJ, Oh MK, Alemzadeh N, Rivera S, Jimenez SA, Rattan S, Cohen S, Dimarino AJ (2004) Impaired rectoanal inhibitory response in scleroderma (systemic sclerosis): an association with fecal incontinence. Dig Dis Sci 49:1040–1045PubMedCrossRef
77.
go back to reference Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN (2002) Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 97:194–197PubMedCrossRef Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN (2002) Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 97:194–197PubMedCrossRef
78.
go back to reference Wang SJ, Lan JL, Lan JL, Chen DY, Chen YH, Hsieh TY, Lin WY (2002) Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol 21:271–274PubMedCrossRef Wang SJ, Lan JL, Lan JL, Chen DY, Chen YH, Hsieh TY, Lin WY (2002) Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol 21:271–274PubMedCrossRef
79.
80.
go back to reference Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA (2002) Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut 51:881–883PubMedCrossRef Kenefick NJ, Vaizey CJ, Nicholls RJ, Cohen R, Kamm MA (2002) Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut 51:881–883PubMedCrossRef
81.
go back to reference Norton C, Cody JD, Hosker G (2006) Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev CD002111 Norton C, Cody JD, Hosker G (2006) Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev CD002111
Metadata
Title
Gastrointestinal Manifestations of Systemic Sclerosis
Authors
Robyn Domsic
Kenneth Fasanella
Klaus Bielefeldt
Publication date
01-05-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-0018-8

Other articles of this Issue 5/2008

Digestive Diseases and Sciences 5/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.